Evidence map›Paper›PMID 32883249›Full record

ArticleBMC public health2020

Hepatitis C virus infection characteristics and treatment outcomes in Canadian immigrants.

Curtis L Cooper, Daniel Read, Marie-Louise Vachon, Brian Conway, Alexander Wong, Alnoor Ramji, Sergio Borgia, Ed Tam, Lisa Barrett, Dan Smyth and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC public health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 10 institutions in 2 countries.

Curtis L CooperUniversity of Ottawa, Roger Guindon Hall, 451 Smyth Rd #2044, Ottawa, ON, K1H 8M5, Canada. ccooper@toh.ca.ORCID http://orcid.org/0000-0002-3368-3499
Daniel ReadUniversity of Ottawa, Roger Guindon Hall, 451 Smyth Rd #2044, Ottawa, ON, K1H 8M5, Canada.
Marie-Louise VachonLaval University, Ferdinand Vandry Pavillon, 1050 Avenue de la Médecine, Quebec City, Quebec, G1V 0A6, Canada.
Brian ConwayVancouver Infectious Diseases Centre, 1200 Burrard St, Vancouver, BC, V6Z 2C7, Canada.
Alexander WongUniversity of Saskatchewan, 107 Wiggins Rd, Saskatoon, SK, S7N 5E5, Canada.
Alnoor RamjiUniversity of British Columbia, 317 - 2194 Health Sciences Mall, Vancouver, BC, V6T 1Z3, Canada.
Sergio BorgiaMcMaster University, Michael DeGroote Centre for Learning and Discovery (MDCL) - 3104, 1280 Main Street West, Hamilton, ON, L8S 4K1, Canada.
Ed TamLiver Health Centre, 750 W Broadway, Vancouver, BC, V5Z 1H2, Canada.
Lisa BarrettDalhousie University, 5849 University Ave, Halifax, NS, B3H 4R2, Canada.
Dan SmythDalhousie University, 5849 University Ave, Halifax, NS, B3H 4R2, Canada.
Jordan J FeldToronto General Hospital Research Institute, 200 Elizabeth St, Toronto, ON, M5G 2C4, Canada.
Sam LeeCumming School of Medicine, University of Calgary, 3330 Hospital Drive NW, Calgary, AB, T2N 4N1, Canada.
CANUHC Cohort
Dalhousie University · CAUniversity of Ottawa · CAMcMaster University · CAToronto General Hospital · CAToronto Liver Centre · CAUniversité Laval · CAUniversity of British Columbia · CAUniversity of Calgary · CAUniversity of Saskatchewan · CAVancouver Infectious Diseases Centre · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThere are multiple obstacles encountered by immigrants attempting to engage hepatitis C virus (HCV) care and treatment. We evaluated the diversity and treatment outcomes of HCV-infected immigrants evaluated for Direct Acting Antiviral (DAA) therapy in Canada.

methodsThe Canadian Network Undertaking against Hepatitis C (CANUHC) Cohort contains demographic information and DAA treatment information prospectively collected at 10 Canadian sites. Information on country of origin and race are collected. Characteristics and outcomes (sustained virological response; SVR) were compared by immigration status and race.

resultsBetween January 2016 and May 2018, 725 HCV-infected patients assessed for DAA therapy were enrolled in CANUHC (mean age: 52.66 ± 12.68 years); 65.66% male; 82.08% White, 5.28% Indigenous, 4.64% South East Asian, 4.64% East Indian, 3.36% Black). 18.48% were born outside of Canada. Mean age was similar [immigrants: 54.36 ± 13.95 years), Canadian-born: 52.27 ± 12.35 years); (p = 0.085)]. The overall baseline fibrosis score (in kPa measured by transient elastography) was similar among Canadian and foreign-born patients. Fibrosis score was not predicted by race or genotype. The proportion initiating DAA therapy was similar by immigrant status (56.72% vs 49.92%). SVR rates by intent-to-treat analysis were similar (immigrants-89.47%, Canadian-born-92.52%; p = 0.575).

conclusionA diverse immigrant population is engaging care in Canada, initiating HCV antiviral therapy in an equitable fashion and achieving SVR proportions similar to Canada-born patients. Our Canadian experience may be of value in informing HCV elimination efforts in economically developed regions.

Indexed as

Emigrants and ImmigrantsHepatitis CHepatitis C, ChronicAdultAgedAntiviral AgentsCanadaFemaleHepacivirusHumansMaleMiddle AgedTreatment OutcomeAntiviral AgentsAntiviral drugsEmigrants and immigrantsHepatitis CSustained Virological response

Identifiers

PMID32883249
PMCPMC7469277
OpenAlexW3082135255

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.